Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has announced it will report its second quarter 2024 financial results on August 7, 2024. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Investors can access the call via phone or through a live webcast available on the company's website. A replay of the webcast will be archived for future reference. This announcement indicates Kymera's commitment to transparency and regular communication with investors regarding its financial performance and progress in developing new small molecule medicines using TPD technology.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) therapies, will participate in a fireside chat at the UBS Virtual TPD Day.
The event is scheduled for July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be accessible on the company's website under the 'News and Events' section in the Investors area. An archived replay will be available post-event.
Kymera Therapeutics announced that Sanofi will expand the ongoing Phase 2 trials for KT-474 (SAR444656) in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) after an interim review of safety and efficacy data. The expansion aims to accelerate progress toward pivotal studies. CEO Nello Mainolfi highlighted KT-474's potential to address significant unmet needs in large markets. Further details on trial designs and updated timings will be provided as the expanded Phase 2 trials progress.
Kymera Therapeutics presented new clinical data from its ongoing Phase 1 trial of KT-333, a STAT3 degrader, at the EHA Annual Meeting. KT-333 showed promising results in treating various hematological malignancies, including complete responses in two Hodgkin's lymphoma patients. The trial enrolled 47 patients across seven dose levels, achieving up to 95% STAT3 degradation. Notably, KT-333 was well-tolerated, showing mostly minor side effects. The company plans to continue dose escalation and expects to release more data in the second half of 2024.
Kymera Therapeutics presented new clinical data from its ongoing Phase 1 trial of KT-253, an MDM2 degrader, at the ASCO Annual Meeting. Results showed initial clinical proof of concept with efficacy in patients with tumor types such as MCC and AML. KT-253 demonstrated target engagement and upregulation of p53 pathway biomarkers even at low doses. The compound was generally well tolerated without the hematologic adverse events seen with traditional MDM2 inhibitors. The trial continues with more data expected in the second half of 2024.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD), announced its participation in the Jefferies 2024 Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The Jefferies conference will take place in New York on June 5 at 11:30 a.m. ET, while the Goldman Sachs event will be held in Miami on June 11 at 2:40 p.m. ET. Both events will feature live webcasts, accessible through Kymera's website, with replays available post-events.
Kymera Therapeutics announced new clinical data for KT-253, an MDM2 degrader, from its ongoing Phase 1 trial. The data will be presented at the ASCO Annual Meeting from May 31 to June 4, 2024.
The study includes 18 patients, indicating promising results in tumor response and a favorable safety profile. Partial and complete responses were observed in patients with Merkel cell carcinoma and acute myeloid leukemia, respectively. KT-253 was well-tolerated, with common adverse events being nausea, fatigue, and headache. Further data will be shared later this year.
Kymera Therapeutics presented new preclinical data for KT-621, an oral STAT6 degrader, at the ATS Annual Meeting. KT-621 showed comparable or superior activity to dupilumab in asthma models, inhibiting key cytokines and chemokines involved in TH2 inflammation. Additional data were shared at Digestive Disease Week, showing KT-621's effects on esophageal smooth muscle cells related to eosinophilic esophagitis. Phase 1 trials for KT-621 are expected to start in the second half of 2024, with data anticipated by the first half of 2025. KT-621 aims to offer a convenient oral treatment for asthma and other TH2 respiratory diseases, potentially transforming current treatment paradigms.
Kymera Therapeutics (NASDAQ: KYMR) announced new Phase 1 data for KT-333, a STAT3 degrader, set to be presented at the European Hematology Association (EHA) Annual Meeting from June 13-16, 2024. The data cut-off date was February 6, 2024. The ongoing study involves 39 patients with various hematologic and solid tumors. Key highlights include two complete responses in classic Hodgkin's lymphoma patients, three partial responses in cutaneous T-cell lymphoma patients, and stable disease in four solid tumor patients. KT-333 achieved a maximum degradation of 97.5% in peripheral blood mononuclear cells, showing favorable immunomodulatory responses. The drug was generally well-tolerated, though two dose-limiting toxicities were observed. Kymera plans to share more data in the second half of 2024.
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in investor conferences in May 2024. They will be attending events like the BofA Securities 2024 Health Care Conference and the TD Cowen 5th Annual Oncology Innovation Virtual Summit. The Company aims to showcase its progress in developing small molecule medicines through targeted protein degradation (TPD).